GlassScriptPhysician profile
Thomas Ford Barkley
NPI 1376540229
$2,759.80
in general payments reported to CMS, 2019-2025
32 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $359 · 2021: $456 · 2022: $433 · 2023: $364 · 2024: $395 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.70 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $451.96 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $379.20 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $245.37 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $205.07 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $171.94 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $126.00 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.91 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.04 | 2023-2024 | Ofev |
| Bausch Health US, LLC | $99.16 | 2021-2023 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $78.00 | 2020-2022 | |
| Allergan, INC. | $74.99 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $73.57 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $62.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.70 | 2022-2023 | |
| Pfizer INC. | $52.15 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $49.86 | 2023-2024 | Rexulti |
| Mylan Specialty L.P. | $48.07 | 2019-2020 | |
| Melinta Therapeutics, LLC | $44.84 | 2019-2020 | |
| Astellas Pharma US INC | $35.67 | 2021-2023 | Veozah |
| Genentech USA, INC. | $34.29 | 2020-2022 | |
| Amarin Pharma, INC. | $33.89 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.16 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $27.18 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $25.63 | 2019 | |
| Boston Scientific Corporation | $21.21 | 2024 | Watchman Flx |
| Clarus Therapeutics INC. | $19.71 | 2021 | |
| Abbott Laboratories | $19.32 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $19.26 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.28 | 2024 | Voquezna |
| Pacira Therapeutics, INC. | $17.18 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.19 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Barkley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.